发布日期：2023-07-07英文标题：NCCN Clinical Practice Guidelines in Oncology：B-Cell Lymphomas（ Version 5.2023）制定者：

美国国家综合癌症网络

出处：NCCN官网摘要：

1.指南来源（Guide Source）: 

 NCCN临床实践指南:B细胞淋巴瘤 V5.2023.发布已获NCCN肿瘤学临床实践指南(NCCN指南®)许可。©2022美国国家综合癌症网络公司.保留所有权利。未经NCCN明确的书面许可，不得出于任何目的以任何形式复制NCCN指南®和文中的插图。要查看NCCN指南的最新完整版本，请访问NCCN.org。NCCN指南是一项持续进行的工作，可能会随着新的重要数据的出现而不断完善。 

2.免责声明（Disclaimers）：

 NCCN对其内容、使用或应用不做任何形式的担保，并否认以任何方式对其应用或使用承担任何责任。

在下载本篇指南前，请先您详细阅读并同意以下协议：

NCCN内容不得用于商业目的，以及NCCN作为NCCN内容的许可方，不作任何陈述或保证，并明确否认NCCN指南适用于任何特定患者的护理或治疗，任何医院、寻求使用《NCCN指南》治疗患者的临床医生或其他医疗服务提供者(“提供者”)应根据特定患者护理或治疗的具体临床情况做出独立的医疗判断，NCCN不建议、推荐或认可任何提供者(无论是否与被许可方相关)进行任何有偿或无偿的医疗治疗、咨询或服务，也不应因被许可方建议、推荐或认可任何此类提供者的作为或不作为而直接或间接承担责任。详见《NCCN最终用户许可协议》

3. 专家名单（Staff）： 

Andrew D. Zelenetz, MD, PhD/Chair † ÞMemorial Sloan Kettering Cancer Center

Leo I. Gordon, MD/Vice Chair ‡ ξRobert H. Lurie Comprehensive Cancer Center of Northwestern University

Jeremy S. Abramson, MD † ‡Massachusetts General Hospital Cancer Center

Ranjana H. Advani, MD † Stanford Cancer Institute

Nancy L. Bartlett, MD † Siteman Cancer Center at BarnesJewish Hospital and Washington University School of Medicine

L. Elizabeth Budde, MD, PhD † ξ City of Hope National Medical Center

Paolo F. Caimi, MD ‡ † Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute

Julie E. Chang, MD ‡ University of Wisconsin Carbone Cancer Center

Beth Christian, MD † The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute

Sven De Vos, MD, PhD ‡ ÞUCLA Jonsson Comprehensive Cancer Center

Bhagirathbhai Dholaria, MD ‡ ξVanderbilt-Ingram Cancer Center

Bita Fakhri, MD † UCSF Helen Diller Family Comprehensive Cancer Center

Luis E. Fayad, MD ‡ Þ †The University of Texas MD Anderson Cancer Center

Thomas M. Habermann, MD ‡ ξMayo Clinic Cancer Center

Muhammad Saad Hamid, MD ‡ St. Jude Children's Research Hospital/The University of Tennessee Health Science Center

Francisco Hernandez-Ilizaliturri, MD † Roswell Park Comprehensive Cancer Center

Boyu Hu, MD † ‡ Þ Huntsman Cancer Institute at the University of Utah

Mark S. Kaminski, MD † University of Michigan Rogel Cancer Center

Christopher R. Kelsey, MD § Duke Cancer Institute

Nadia Khan, MD † Fox Chase Cancer Center

Rebecca King, MD ≠ Mayo Clinic Cancer Center

Susan Krivacic, MPAff ¥ Consultant

Ann S. LaCasce, MD † Dana-Farber/Brigham and Women’s Cancer Center

Megan Lim, MD, PhD ≠ Abramson Cancer Center at the University of Pennsylvania

Mayur Narkhede, MD † ‡ O'Neal Comprehensive Cancer Center at UAB

Rachel Rabinovitch, MD § University of Colorado Cancer Center

Praveen Ramakrishnan, MD, MS ‡ UT Southwestern Simmons Comprehensive Cancer Center

Erin Reid, MD ‡ UC San Diego Moores Cancer Center

Kenneth B. Roberts, MD § Yale Cancer Center/Smilow Cancer Hospital

Hayder Saeed, MD † ‡ Þ Moffitt Cancer Center

Stephen D. Smith, MD ‡ Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance

Jakub Svoboda, MD ‡ Abramson Cancer Center at the University of Pennsylvania

Lode J. Swinnen, MB, ChB † ‡ ξ The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Joseph Tuscano, MD ‡ UC Davis Comprehensive Cancer Center

Julie M. Vose, MD, MBA ‡ ξ Fred & Pamela Buffett Cancer Center

4.临床试验（Clinical Trials）：

NCCN认为任何癌症患者都可以在临床试验中得到最佳治疗，因此特别鼓励患者参与临床试验。 寻找NCCN成员组：https://www.nccn.org/home/member-institutions

5.NCCN对证据和共识分类（ NCCN Categories of Evidence and Consensus）：

推荐均为2A类，除非另有说明，请参见下表：

6.NCCN首选分类（ NCCN Categories of Preference）：

   所有建议均视为合理，请参见下表：

B细胞淋巴瘤（2023.V5）指南下载